Call for proposals for personalising health and care H2020-PHC-2015-two-stage Closed!

Objectives

The Framework Programme for Research and Innovation (2014-2020) is implemented by specific programme and work programmes.

The “Societal challenges” responds directly to the policy priorities and societal challenges that are identified in the Europe 2020 strategy and that aim to stimulate the critical mass of research and innovation efforts needed to achieve the Union's policy goals.

The specific objective is to fully exploit the potential of Europe's talent pool and to ensure that the benefits of an innovation-led economy are both maximised and widely distributed across the Union in accordance with the principle of excellence.

Funding shall be focused on the following specific objectives:
(a) Health, demographic change and well-being.
(b) Food security, sustainable agriculture and forestry, marine, maritime and inland water research. and the bioeconomy.
(c) Secure, clean and efficient energy.
(d) Smart, green and integrated transport.
(e) Climate action, environment, resource efficiency and raw materials.
(f) Europe in a changing world - Inclusive, innovative and reflective societies.
(g) Secure societies - Protecting freedom and security of Europe and its citizens.

Actions

Actions foreseen within this call for proposals include the following topics:

  • PHC-04-2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions. Better health promotion and disease prevention interventions can make a significant contribution to equitable health improvements and thus the sustainability of health and care systems. A “health in all policies” approach has been identified as a promising means to stimulate and foster environments that support health, wellbeing and behavioural change. This requires a multi-sector approach that aims to improve health by addressing such factors as housing; water and sanitation systems; transportation; exposure to chemicals and their mixtures; communication, education and information; occupational factors, physical activity, food production and distribution, and the physical, natural and social environments.
  • PHC-14-2015: New therapies for rare diseases. A considerable amount of knowledge has been generated by biomedical research in recent years, yet most of the 6000-8000 rare diseases are lacking therapies despite many diseases being life-threatening or chronically debilitating. Specific problems posed in therapy development for rare diseases include the small and dispersed patient populations and the nature of the therapies proposed which are often highly specialised and novel requiring the engagement of regulatory authorities during development. In addition the limited market for such therapies provides a low commercial return.
  • PHC-16-2015: Tools and technologies for advanced therapies. For their successful application, new therapies, such as gene or cell therapies, tissue engineering or regenerative medicine often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and GMP standards at reasonable cost is often underestimated. In addition, specific attention needs to be given to aspects such as miniaturisation, automation, biomaterials and scaffold construction while advanced methods and devices for targeted and controlled delivery, and monitoring technology, are needed to bring these innovative treatments to the patient.
  • PHC-22-2015: Promoting mental wellbeing in the ageing population. Health and care of the rapidly growing older population in Europe and elsewhere poses a number of specific challenges. Among these, the burden posed by mental and neurological conditions on older citizens has a significant impact on their working capacity, quality of life and that of their care givers, and interacts with the course and treatment of comorbidities which are frequently associated with old age. Although some mental disorders like depression, anxiety, insomnia, dementia, personality disorders and substance use-related disorders are not limited only to older people and may have their origins in events experienced earlier in the lifespan, they are often present in clinical forms specific to older people, and may require adapted therapeutic approaches. In addition, non-age-specific mental illnesses may complicate or contribute to other, more specific age-related chronic disorders. The prevalence of these disorders is high and increasing, and difficulties in their treatment are compounded by the underrepresentation or even exclusion of older persons from many clinical trials in the field of psychiatry.
  • PHC-24-2015: Piloting personalised medicine in health and care systems. Personalised medicine has the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities and in doing so contribute to the sustainability of health and care systems. If this potential is to be realised at a larger scale it must first be demonstrated in terms of sustainable benefits, and as a new model of care organisation. Demonstration is however complicated by the diversity of European Union health systems.
  • PHC-11-2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies. The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving, and often complex technologies. Improved clinical decisions based on new and improved diagnostic tools and techniques should lead to better health outcomes while contributing to the sustainability of the health care system.
  • PHC-18-2015: Establishing effectiveness of health care interventions in the paediatric population. Knowledge about the overall benefit of healthcare interventions in the paediatric population is currently limited and may result in inappropriate interventions with acute or potentially lifelong impact on health and well-being. Increasing knowledge in the areas of intervention effectiveness and clinical research has the potential to achieve system-wide improvements in health care quality and health outcomes. Effectiveness research in children and adolescents is required which is targeted, designed, conducted, and reported in ways that include clinically important differences in the type and course of disease in children.
  • PHC-33-2015: New approaches to improve predictive human safety testing. Current approaches assessing the safety of chemical substances in humans are expensive and time consuming, and may be of limited relevance as a predictor of adverse effects. Better approaches are needed both to improve the efficiency of predictive toxicological testing to address key areas of concern for human health and to meet regulatory requirements. Safety testing is of worldwide concern and therefore international cooperation may be an important element in addressing the challenge.
  • PHC-02-2015: Understanding disease: systems medicine. The development of new, evidence-based treatments relies on an improved understanding of the often very complex pathophysiology of diseases. Systems (bio) medicine approaches have the potential to tackle this complexity through the integration of a variety of biological and medical research data and computational modelling. A European collaborative approach is required to assemble the necessary multidisciplinary expertise (e.g. biology, medicine, mathematics, computational technologies) for implementing systems (bio) medicine approaches.
  • PHC-03-2015: Understanding common mechanisms of diseases and their relevance in co-morbidities. The development of new treatments is greatly facilitated by an improved understanding of the pathophysiology of diseases. There is therefore a need to address the current knowledge gaps in disease aetiology in order to support innovation in the development of evidence-based treatments. In this context, a better understanding of the mechanisms that are common to several diseases, in particular of those leading to co-morbidities, constitutes an important challenge.

European community funding

The Community provisional funding available for the call for proposals is:

  • 306,00 Million EUR (Global Budget)

All the important deadlines

  • 14 October 2014 - 5 years ago (Deadline for the presentation of proposals)

Further information about the call

Official webpage of the call

Useful documents

  • Personalising health and care (Legal base)

Organisations eligible to participate

Opened to the following bodies or institutes with legal status established in the covered areas:

  • Any legal organisation

Covered areas

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

  • European Union (EU)

Directorate-Generale responsible

Directorate-General for Research

Related calls for proposals

Related calls

Explore other programmes